China Cord Blood Corporation (NYSE:CO) was up 7.2% during mid-day trading on Friday . The company traded as high as $12.08 and last traded at $12.01. Approximately 544,841 shares changed hands during trading, an increase of 45% from the average daily volume of 376,198 shares. The stock had previously closed at $11.20.
Separately, BidaskClub raised shares of China Cord Blood Corporation from a “buy” rating to a “strong-buy” rating in a report on Tuesday, August 1st.
The firm has a market cap of $1.36 billion, a price-to-earnings ratio of 38.37 and a beta of 0.88. The stock’s 50 day moving average price is $11.39 and its 200 day moving average price is $10.15.
China Cord Blood Corporation (NYSE:CO) last released its earnings results on Wednesday, August 23rd. The medical research company reported $0.09 earnings per share for the quarter. China Cord Blood Corporation had a net margin of 22.07% and a return on equity of 8.64%. The company had revenue of $33.07 million for the quarter. Equities analysts forecast that China Cord Blood Corporation will post $0.15 earnings per share for the current fiscal year.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Parametrica Management Ltd lifted its stake in shares of China Cord Blood Corporation by 1,842.1% during the 3rd quarter. Parametrica Management Ltd now owns 304,903 shares of the medical research company’s stock valued at $3,391,000 after buying an additional 289,203 shares in the last quarter. Nationwide Fund Advisors purchased a new position in shares of China Cord Blood Corporation during the 3rd quarter valued at $372,000. Arrowstreet Capital Limited Partnership purchased a new position in shares of China Cord Blood Corporation during the 2nd quarter valued at $493,000. State Street Corp lifted its stake in shares of China Cord Blood Corporation by 1.7% during the 2nd quarter. State Street Corp now owns 30,056 shares of the medical research company’s stock valued at $284,000 after buying an additional 506 shares in the last quarter. Finally, Virtu KCG Holdings LLC purchased a new position in shares of China Cord Blood Corporation during the 2nd quarter valued at $199,000. Institutional investors own 12.60% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece was first posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.com-unik.info/2017/10/29/china-cord-blood-corporation-co-trading-up-7-2.html.
China Cord Blood Corporation Company Profile
China Cord Blood Corporation is a provider of cord blood banking services in China. The Company and its subsidiaries are principally engaged in the provision of umbilical cord blood storage and ancillary services in the People’s Republic of China. It provides cord blood testing, processing and storage services under the direction of subscribers for a cord blood processing fee and a storage fee.
What are top analysts saying about China Cord Blood Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for China Cord Blood Corporation and related companies.